- Report
- April 2024
- 185 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- December 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- August 2024
- 180 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- August 2024
- 130 Pages
North America
From €3797EUR$4,000USD£3,203GBP
- Report
- February 2023
- 150 Pages
United States
From €2364EUR$2,490USD£1,994GBP
From €3323EUR$3,500USD£2,803GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3323EUR$3,500USD£2,803GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3323EUR$3,500USD£2,803GBP
- Report
- February 2024
- 182 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- February 2023
- 155 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- February 2025
- 85 Pages
India
From €3323EUR$3,500USD£2,803GBP
- Report
- February 2024
- 120 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- November 2023
- 160 Pages
Global
From €3417EUR$3,599USD£2,882GBP
- Report
- January 2024
- 353 Pages
Global
€4742EUR$4,995USD£4,000GBP

Minimally invasive biopsy is a procedure typically used in the field of diagnostic medicine to obtain a tissue sample from the patient without the need for a traditional, larger-scale surgical approach. As part of the in vitro diagnostics (IVD) landscape, minimally invasive biopsies play an essential role in the early detection, diagnosis, and monitoring of various diseases, including cancer. These procedures are favored for their ability to reduce patient discomfort, lower the chances of complications, and shorten recovery times compared to conventional surgical biopsies.
Within the in vitro diagnostics market, technologies associated with minimally invasive biopsies include image-guided biopsy systems, fine-needle aspirations, and core needle biopsies among others. Many of these procedures are guided by diagnostic imaging technologies such as ultrasound, CT scanning, and MRI. Advances in these areas lead to enhancements in precision and accuracy of tissue sampling. The integration of such biopsies with molecular diagnostic techniques is increasingly prevalent, allowing for detailed analysis that can inform patient-specific treatment approaches.
Several prominent companies operating in the minimally invasive biopsy market include Becton Dickinson and Company, Hologic Inc., Leica Biosystems, Medtronic, and Boston Scientific Corporation. These companies have a strong presence in the diagnostic field and continue to innovate with new products and technologies that enable less invasive and more accurate biopsy procedures. Show Less Read more